(Q43622918)

25 November 2017

title

Vigabatrin visual toxicity: evolution and dose dependence (English)

1 reference

25 November 2017

Malmgren K

1

1 reference

25 November 2017

Ben-Menachem E

series ordinal

2

1 reference

25 November 2017

Frisén L

series ordinal

3

1 reference

25 November 2017

publication date

1 May 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

42

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

609-615

1 reference

The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Neuropathology of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Vigabatrin: no microvacuoles in a human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Visual field defects associated with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Visual disorders caused by diphenylhydantoin: clinical and electro-ophthalmologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Diazepam and its effects on visual fields

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

The blood-ocular barriers: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

Characteristics of a unique visual field defect attributed to vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

High-pass resolution perimetry. A clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.28600.X

10.1046/J.1528-1157.2001.28600.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference